Immuneering
Immuneering is a United States-based biotechnology company running 2 late-stage cancer trials of Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer.
Overview
Immuneering, based in Cambridge, the United States, is a biotechnology company. Immuneering is a biotechnology company developing oncology treatments based on 'Deep Cyclic Inhibitors', a pulsed dosing approach to MAPK-pathway inhibition intended to reduce cancer resistance while improving tolerability. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer. The largest, NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), plans to enrol 510 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
Similar pages
not linked directly; found by shared links- CompanyKrystal Biotech
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyiOnctura
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyOrion, Orion Pharma
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai Juncell Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.